22q11.2缺失综合征的产前与产后诊断:至1岁龄的心脏与非心脏结局
这项多中心回顾性队列研究纳入2006至2019年625例1岁内确诊22q11.2缺失综合征的胎儿、新生儿或婴儿,比较产前诊断或疑似与产后诊断的围产期及婴儿结局。产前组的分娩管理改善,新生儿心脏失代偿及1岁龄喂养困难更少,但1年死亡率无差异。
要点
- 产前组较产后组在当地社区医院分娩的比例更低(5.1% vs 38.2%)。
- 产前组新生儿心脏失代偿比例更低(1.3% vs 5.0%)。
- 产前组1岁龄喂养困难比例更低(43.4% vs 50.3%)。
核心结论
- 与产后诊断相比,22q11.2缺失综合征的产前发现与分娩管理改善及更少的心脏和非心脏疾病相关,但与死亡率无关。
研究设计与样本
- 多中心回顾性队列研究,覆盖2006至2019年30个国际中心、4个大洲。
- 纳入1岁龄前经遗传学确诊22q11.2缺失综合征的胎儿、新生儿或婴儿,伴或不伴先天性心脏病,共625例(53.4%为男性)。
- 产前诊断或疑似组包括259例胎儿(其中156例活产,60.2%)和122例产前疑似产后确诊新生儿,产后诊断组244例婴儿。
- 活产队列共522例,评估围产期管理、心脏和非心脏疾病及1岁内死亡率。
- 结局对危重先天性心脏病、出生胎龄和中心进行了校正。
主要发现
- 活产队列1年死亡率为5.9%,两组间无差异,但随危重先天性心脏病(风险比4.18;95%置信区间1.56-11.18;P<.001)和出生胎龄(每增加1周风险比0.78;95%置信区间0.69-0.89;P<.001)而变化。
- 校正危重先天性心脏病和出生胎龄后,产前组较产后组在当地社区医院分娩的比例更低(5.1% vs 38.2%;比值比0.11;95%置信区间0.06-0.23;P<.001)。
- 校正后,产前组较产后组新生儿心脏失代偿的比例更低(1.3% vs 5.0%;比值比0.11;95%置信区间0.03-0.49;P=.004)。
- 校正后,产前组较产后组1岁龄喂养困难的比例更低(43.4% vs 50.3%;比值比0.58;95%置信区间0.36-0.91;P=.019)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The 22q11.2 deletion syndrome is the most common microdeletion syndrome and is frequently associated with congenital heart disease. Prenatal diagnosis of 22q11.2 deletion syndrome is increasingly offered. It is unknown whether there is a clinical benefit to prenatal detection as compared with postnatal diagnosis. OBJECTIVE: This study aimed to determine differences in perinatal and infant outcomes between patients with prenatal and postnatal diagnosis of 22q11.2 deletion syndrome. STUDY DESIGN: This was a retrospective cohort study across multiple international centers (30 sites, 4 continents) from 2006 to 2019. Participants were fetuses, neonates, or infants with a genetic diagnosis of 22q11.2 deletion syndrome by 1 year of age with or without congenital heart disease; those with prenatal diagnosis or suspicion (suggestive ultrasound findings and/or high-risk cell-free fetal DNA screen for 22q11.2 deletion syndrome with postnatal confirmation) were compared with those with postnatal diagnosis. Perinatal management, cardiac and noncardiac morbidity, and mortality by 1 year were assessed. Outcomes were adjusted for presence of critical congenital heart disease, gestational age at birth, and site. RESULTS: A total of 625 fetuses, neonates, or infants with 22q11.2 deletion syndrome (53.4% male) were included: 259 fetuses were prenatally diagnosed (156 [60.2%] were live-born) and 122 neonates were prenatally suspected with postnatal confirmation, whereas 244 infants were postnatally diagnosed. In the live-born cohort (n=522), 1-year mortality was 5.9%, which did not differ between groups but differed by the presence of critical congenital heart disease (hazard ratio, 4.18; 95% confidence interval, 1.56-11.18; P<.001) and gestational age at birth (hazard ratio, 0.78 per week; 95% confidence interval, 0.69-0.89; P<.001). Adjusting for critical congenital heart disease and gestational age at birth, the prenatal cohort was less likely to deliver at a local community hospital (5.1% vs 38.2%; odds ratio, 0.11; 95% confidence interval, 0.06-0.23; P<.001), experience neonatal cardiac decompensation (1.3% vs 5.0%; odds ratio, 0.11; 95% confidence interval, 0.03-0.49; P=.004), or have failure to thrive by 1 year (43.4% vs 50.3%; odds ratio, 0.58; 95% confidence interval, 0.36-0.91; P=.019). CONCLUSION: Prenatal detection of 22q11.2 deletion syndrome was associated with improved delivery management and less cardiac and noncardiac morbidity, but not mortality, compared with postnatal detection.
引用
- Freud LR, Galloway S, Crowley TB, et al. Prenatal vs postnatal diagnosis of 22q11.2 deletion syndrome: cardiac and noncardiac outcomes through 1 year of age. Am J Obstet Gynecol. 2023. PMID: 37717890. doi:10.1016/j.ajog.2023.09.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。